Chemistry of Materials
ARTICLE
passed continuously through the clear solution for 24 h at 50 °C. The
mixture was then concentrated and the crude product was purified by
column chromatography (ethyl acetate/THF, 2/1, v/v, Rf = 0.48).
Product 3 was obtained as a colorless, highly viscous oil (1.01 g, 0.93
2,2,4,4,6,6-Hexakis-(4-ethyl-5-(4-butoxy)-1,3-dioxolan-2-one)-cy-
clotriphosphazene (9). Chlorocobalt tetraphenylporphyrin ((TTP)
CoIIICl) catalyst was synthesized following a reported procedure.20ꢀ22
A stainless steel autoclave (250 mL) was charged with a solution of 8
(0.50 g, 0.50 mmol), (TPP)CoIIICl (2 mol %) and N,N-dimethylami-
nopyridine (DMAP, 4 mol %) in 15 mL methylene chloride. After
purging with nitrogen, the reaction was started by pressurization of the
solution with CO2 up to 50 bar. The mixture was then heated to 100 °C
accompanied by a pressure increase to 80 bar and stirred for 72 h at this
temperature. The autoclave was allowed to cool to room temperature
and excess CO2 was discharged. The mixture was concentrated, and the
crude product was purified by column chromatography (ethyl acetate/n-
hexane, 5/1, v/v, Rf = 0.25). Product 9 was obtained as slightly orange,
highly viscous oil (0.42 g, 3.34 mmol, 67% yield). 1H NMR (CDCl3, 250
MHz): δ 1.03 (t, 18H, 3J = 7.3, —CH3), 1.36ꢀ1.83 (m, 48H, —CH2CH3,
—OCH2(CH2)3—), 3.90 (br, 12H, —OCH2—), 4.13ꢀ4.30 (m, 0.72 H,
trans-CH2—CH—(O(CdO)O)—CH—C2H5), 4.48ꢀ4.72 (m, 11.28
H, cis-CH2—CH—(O(CdO)O)—CH—C2H5). 13C NMR (CDCl3,
250 MHz): δ 10.3, 22.4, 22.5, 28.7, 29.9, 65.7, 80.0, 81.5, 154.9. 31P
NMR (CDCl3, 700 MHz): δ 18.57 (s). MALDI-TOF m/z (%) 1258
(100).
1
mmol, 57% yield). H NMR (DMSO, 250 MHz): δ 1.23ꢀ1.51 (m,
12H, —OCH2CH2CH2—), 1.52ꢀ1.83 (m, 24H, —OCH2CH2—, —
CH2CH—(O(CdO)O)—CH2), 3.84 (m, 12H, —OCH2—), 4.11
2
3
(dd, 6H, J = 8.0, J = 7.2, —CH—(O(CdO)O)—CH2), 4.56 (dd,
6H, 2J = 8.1, 3J = 7.2, —CH—(O(CdO)O)—CH2), 4.73ꢀ4.84 (m,
6H, —CH—(O(CdO)O)—CH2). 13C NMR (DMSO, 250 MHz):
δ 20.5, 29.2, 32.4, 64.9, 69.2, 76.9, 154.9. 31P NMR (DMSO, 500
MHz): δ 17.21 (s). MALDI-TOF m/z (%) 1090 (100).
2,2,4,4,6,6-Hexakis-(9-decenyl-1-oxy)-cyclotriphosphazene (4).
Synthetic procedure followed that for compound 1 to afford 4 as
colorless liquid (column chromatography, n-hexane/ethyl acetate, 4/1,
v/v, Rf = 0.88, 82% yield). 1H NMR (CDCl3, 250 MHz): δ 1.17ꢀ1.44
(m, 60H, —OCH2CH2—(CH2)5—), 1.52ꢀ1.70 (m, 12H, —OCH2
CH2—), 1.94ꢀ2.06 (m, 12H, —CH2—CHd), 3.82ꢀ3.92 (m, 12H, —
OCH2—), 4.85ꢀ5.01 (m, 12H, dCH2), 5.69ꢀ5.85 (m, 6H, —
CHdCH2). 13C NMR (CDCl3, 250 MHz): δ 25.9, 29.1, 29.3, 29.5,
29.6, 30.5, 34.0, 66.0, 114.4, 139.3. 31P NMR (CDCl3, 700 MHz):
δ 17.85 (s). MALDI-TOF m/z (%) 1067 (100).
2,2,4,4,6,6-Hexakis-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)-
cyclotriphosphazene (10).23. Synthetic procedure followed that for
compound 1 to afford 10 as colorless oil (column chromatography, n-
2,2,4,4,6,6-Hexakis-(8-(oxiran-2-yl)-oct-1-oxy)-cyclotriphospha-
zene (5). Synthetic procedure followed that for compound 2 to afford 5
as slightly orange, viscous oil in 78% yield (column chromatography,
n-hexane/ethyl acetate, 10/1, v/v, passing over to pure ethyl acetate,
Rf,n-hexane/ethylacetate,5/1 = 0.2). 1H NMR (CDCl3, 250 MHz): δ 1.18ꢀ1.71
(m, 84H, ꢀOCH2ꢀ(CH2)7ꢀ), 2.44 (dd, 6H, 2J = 5.2, 3J = 2.6, ꢀCHꢀ-
(ꢀOꢀ)ꢀCH2), 2.73 (dd, 6H, 2J = 5.1, 3J = 4.0, ꢀCHꢀ(ꢀOꢀ)ꢀCH2),
2.82ꢀ2.92 (m, 6H, ꢀCHꢀ(ꢀOꢀ)ꢀCH2), 3.79ꢀ3.95 (m, 12H,
ꢀOCH2ꢀ). 13C NMR (CDCl3, 250 MHz): δ 25.9, 26.2, 29.4, 29.6,
29.7, 30.5, 32.7, 47.3, 52.6, 66.0. 31P NMR (DMSO, 700 MHz): δ17.25 (s).
2,2,4,4,6,6-Hexakis-(4-(8-octoxy)-1,3-dioxolan-2-one)-cyclotri-
phosphazene (6). Synthetic procedure followed that for compound 3 to
afford 6asslightlyyellow, viscousoil(columnchromatography,n-hexane/
1
hexane/THF, 1/3, v/v, Rf = 0.28, 90% yield). H NMR (CDCl3, 250
MHz): δ 3.34 (s, 18H, —CH3), 3.48ꢀ3.54 (m, 12H, P—OCH2CH2—),
3.55ꢀ3.68 (m, 72H, —O—(CH2CH2O)3—CH3), 4.00 (br, 12H, P—
OCH2—). 13C NMR (CDCl3, 250 MHz): δ 59.3, 65.2, 70.2, 70.7, 70.8,
72.1. 31P NMR (CDCl3, 700 MHz): δ 17.11 (s). MALDI-TOF m/z (%)
1379 (100).
2. HPB-Based Model Compounds
Hexakis-(4-(hept-4-enoate)-phenyl)-benzene (11). 6-Heptenoyl
chloride was synthesized following a reported procedure.24 Hexakis-
(4-hydroxyphenyl)-benzene25 (0.20 g, 0.32 mmol) and dry pyridine
(125 mL) were mixed at 60 °C in a Schlenk flask. Under an N2
atmosphere, a solution of 6-heptenoyl chloride (0.56 g, 3.81 mmol) in
5 mL dry acetonitrile was added dropwise at 60 °C under stirring. The
temperature was increased to 85 °C, and the mixture was stirred at this
temperature for 24 h. Subsequently, 15 mL acetonitrile, 15 mL ethyl
acetate, and 15 mL water were added, and the organic phase was washed
three times with 10 mL of 15 wt % aqueous sodium carbonate and once
with 15 mL water. The combined organic layer was dried over MgSO4,
concentrated, and the residue was subjected to column chromatography
with n-hexane/ethyl acetate (3/1, v/v, Rf = 0.65) as eluent. Product 11
was obtained as a white powder (0.35 g, 0.27 mmol, 84% yield). 1H NMR
(CDCl3, 250 MHz): δ 1.35ꢀ1.51 (m, 12H, —CH2CH2—CHdCH2),
1.57ꢀ1.75 (m, 12H, —O—C(dO)—CH2CH2—), 1.96ꢀ2.13 (m,
1
ethyl acetate, 4/1, v/v, Rf = 0.55, 75% yield). H NMR (CDCl3, 250
MHz): δ 1.17ꢀ1.53 (m, 60H, —OCH2CH2—(CH2)5—), 1.54ꢀ1.82
(m, 24H, —OCH2CH2—, —CH2CH—(O(CdO)O)—CH2), 3.87
(m, 12H, —OCH2—), 4.05 (dd, 6H, 2J = 8.3, 3J = 7.1, —CH
—(O(CdO)O)—CH2), 4.52 (dd, 6H, 2J = 8.2, 3J = 7.1, —CH
—(O(CdO)O)—CH2), 4.64ꢀ4.75 (m, 6H, —CH—(O(CdO)O)
—CH2). 13C NMR (CDCl3, 250 MHz): δ 24.6, 25.9, 29.3, 29.5, 30.4,
34.1, 66.0, 69.6, 77.3, 155.4. 31P NMR (CDCl3, 700 MHz): δ 17.22 (s).
MALDI-TOF m/z (%) 1426 (100).
2,2,4,4,6,6-Hexakis-(cis-5-octenyl-1-oxy)-cyclotriphosphazene (7).
Synthetic procedure followed that for compound 1 to afford 7 as
colorless, viscous liquid (column chromatography, methylene chloride,
Rf = 0.85, 89% yield). 1H NMR (CDCl3, 250 MHz): δ 0.91 (t, 18H, 3J =
7.3, —CH3), 1.31ꢀ1.46 (m, 12H, —OCH2CH2—), 1.54ꢀ1.70 (m,
12H, —OCH2CH2CH2—), 1.92ꢀ2.06 (m, 24H, —CH2—CHdCH
—CH2—), 3.83ꢀ3.92 (m, 12H, -OCH2-), 5.20ꢀ5.40 (m, 12H,
ꢀCH2ꢀCH=CH-CH2ꢀ). 13C NMR (CDCl3, 250 MHz): δ 14.5,
20.7, 26.0, 26.8, 30.0, 65.8, 128.8, 132.2. 31P NMR (CDCl3, 700 MHz):
δ 18.56 (s). MALDI-TOF m/z (%) 898 (100).
3
12H, —CH2—CHdCH2), 2.42 (t, 12H, J = 7.4, —O—C(dO)—
CH2—), 4.88ꢀ5.06 (m, 12H, —CH2—CHdCH2), 5.67ꢀ5.88 (m, 6H,
—CH2—CHdCH2), 6.63 (d, 12H, 3J = 8.7, ortho-ArH), 6.74 (d, 12H,
3J = 8.7, meta-ArH). 13C NMR (CDCl3, 250 MHz): δ 24.5, 28.5, 33.6,
34.4, 115.0, 120.3, 132.4, 137.7, 138.6, 140.2, 148.8, 171.8. MALDI-TOF
m/z (%) 1315 (Naþ-Peak, 100).
Hexakis-(4-(5-oxiran-2-yl-pentanoate)-phenyl)-benzene (12). 11
(0.35 g, 0.27 mmol) was dissolved in 80 mL methylene chloride. The
solution was cooled to 0 °C, and MCPBA (77%, 0.61 g, 2.72 mmol) was
added portionwise. The mixture was stirred vigorously for 96 h. After
complete epoxidation, the mixture was washed three times with 2 wt %
sodium hydroxide solution and water. The organic phase was dried over
MgSO4 and then concentrated to dryness. The crude product 12 was
obtained as white powder and used without further purification (0.36 g,
0.26 mmol, 96% yield). 1H NMR (CDCl3, 250 MHz): δ 1.40ꢀ1.80 (m,
36H, —O—C(dO)—CH2—(CH2)3—), 2.36ꢀ2.50 (m, 18H, —O—
C(dO)—CH2—, —CH—(—O—)—CH2), 2.72 (dd, 6H, 2J = 5.0, 3J =
2,2,4,4,6,6-Hexakis-(4-(3-ethyloxiran-2-yl)-but-1-oxy)-cyclotripho-
sphazene (8). Synthetic procedure followed that for compound 2 to
afford 8 after column chromatography (methylene chloride/ethyl acetate,
1
Rf = 0.85) as slightly yellow, highly viscous oil in 82% yield. H NMR
(DMSO, 250 MHz): δ 0.89ꢀ1.02 (t, 18H, 3J = 7.3, ꢀCH3), 1.35ꢀ1.73
(m, 48H, ꢀCH2CH3, ꢀOCH2ꢀ(CH2)3ꢀ), 2.74ꢀ2.90 (m, 12H, ꢀCHꢀ
(ꢀOꢀ)ꢀCHꢀC2H5), 3.74ꢀ3.90 (m, 12H, ꢀOCH2ꢀ). 13C NMR
(DMSO, 250 MHz): δ 10.5, 20.6, 22.5, 26.6, 29.5, 56.0, 57.1, 64.9. 31P
NMR (DMSO, 700 MHz): δ 18.81 (s). MALDI-TOF m/z (%) 994 (32),
1016 (Naþ-Peak, 32), 1032 (Kþ-Peak, 100).
2122
dx.doi.org/10.1021/cm103559d |Chem. Mater. 2011, 23, 2120–2129